Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer

被引：0
|
作者：
Iosifidou, R. [1 ]
Xepapadakis, G. [2 ]
Venizelos, V. [3 ]
Markopoulos, C. [4 ]
Papazisis, K. [5 ]
Tsoulos, N. [6 ]
Kapetsis, G. [6 ]
Giannoulakis, S. [6 ]
Paraskeva, M. [7 ]
Kaparelou, M. [8 ]
Lainakis, G. [3 ]
Fotarelli, A. [1 ]
Pavlidou, F. [1 ]
Fountzilas, E. [9 ]
Saloustros, E. [10 ]
Karageorgopoulou, S. [2 ]
Triantafillidou, S. [11 ]
Intzes, S. [12 ]
Koinis, F. [10 ]
机构：
[1] Theageneio Hosp, Thessaloniki, Greece
[2] IASO Hosp, Athens, Greece
[3] Metropolitan Hosp, Athens, Greece
[4] Athens Med Ctr, Maroussi, Greece
[5] EuroMed Clin, Thessaloniki, Greece
[6] Genekor SA, Athens, Greece
[7] Gen Hosp Rodos, Rodos, Greece
[8] Alexandra Gen Hosp, Athens, Greece
[9] St Lukes Hosp, Thessaloniki, Greece
[10] Univ Hosp Larisa, Larisa, Greece
[11] Genesis Hosp, Athens, Greece
[12] Interbalcan European Med Ctr, Thessaloniki, Greece
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.103933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P050
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effect of Radiation on Breast Cancer Specific Survival for Elderly Women With Early Stage (T1N0 ER+) Breast Cancer: Review of the SEER Database
    Surapaneni, A.
    Sura, S.
    Rineer, J.
    Schwartz, D.
    Rotman, M.
    Schreiber, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S246 - S246
  • [32] Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
    Unal, Caglar
    Ozmen, Tolga
    Ordu, Cetin
    Pilanci, Kezban Nur
    Ilgun, Ahmet Serkan
    Gokmen, Erhan
    Almuradova, Elvina
    Ozdogan, Mustafa
    Guler, Niluefer
    Uras, Cihan
    Kara, Halil
    Demircan, Orhan
    Isik, Selver
    Alco, Gul
    Saip, Pinar
    Aydin, Esra
    Duymaz, Tomris
    Celebi, Filiz
    Yararbas, Kanay
    Soybir, Gursel
    Ozmen, Vahit
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database.
    Nahleh, Zeina A.
    Hobbs, Brian
    Elimimian, Elizabeth
    Wei, Wei
    Gupta, Annie
    Blake, Cassann N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Prevalence of pn2/n3 Disease in Postmenopausal Women with cn0 ER+/HER2-breast Cancer
    Amlicke, Maire J.
    Park, Jihye
    Agala, Chris B.
    Ray, Emily M.
    Downs-Canner, Stephanie M.
    Spanheimer, Philip M.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 376 - 376
  • [35] Factors Associated With the Decision to Decline Chemotherapy in Patients With Early-stage, ER + /HER2-Breast Cancer and High-risk Scoring on Genomic Assays
    Bilani, Nadeem
    El Ladki, Shereen
    Yaghi, Marita
    Main, Olivia
    Jabbal, Iktej S.
    Elson, Leah
    Zerdan, Maroun Bou
    Liang, Hong
    Nahleh, Zeina
    CLINICAL BREAST CANCER, 2022, 22 (04) : 367 - 373
  • [36] Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer
    Chadha, M.
    White, J.
    Swain, S. M.
    Rakovitch, E.
    Jagsi, R.
    Whelan, T.
    Sparano, J. A.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [37] Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer
    M. Chadha
    J. White
    S. M. Swain
    E. Rakovitch
    R. Jagsi
    T. Whelan
    J. A. Sparano
    npj Breast Cancer, 9
  • [38] Implementation of Oncotype Dx to Guide Chemotherapy Sparing for Women with Postmenopausal N1-3, ER-positive, HER-2-negative Breast Cancer
    Rajakumar, L.
    Glendenning, J.
    Hall, J.
    Burcombe, R.
    McCormick, G.
    Hegarty, G.
    Harper-Wynne, C.
    Brown, B.
    Moss, C.
    Thomas, C.
    Jyothirmayi, R.
    Osman, M.
    Nikiforidis, L.
    CLINICAL ONCOLOGY, 2024, 36 (04) : E111 - E111
  • [39] In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.
    Soliman, Hatem Hussein
    Robson, Mark E.
    Wagner, Susanne
    Flake, Darl D.
    Schwartzberg, Lee Steven
    Sharma, Priyanka
    Magliocco, Anthony Martin
    Kronenwett, Ralf
    Lancaster, Johnathan M.
    Lanchbury, Jerry S.
    Gutin, Alexander
    Gradishar, William John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Elevated breast cancer mortality in young women (<40 years) compared with older women is attributed to poorer survival in early-stage disease
    Gnerlich, Jennifer
    Deshpande, Anjali D.
    Jeffe, Donna B.
    Sweet, Allison
    White, Nick
    Margenthaler, Julie A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 207 (03) : S79 - S79
12345